Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5208132 | Progress in Polymer Science | 2014 | 70 Pages |
Abstract
The presence of a mucus layer that covers the surface of a variety of organs has been capitalized to develop mucoadhesive dosage forms that remain in the administration site for prolonged times, increasing the local and/or systemic bioavailability of the administered drug. The emergence of micro and nanotechnologies together with the implementation of non-invasive and painless administration routes has revolutionized the pharmaceutical market and the treatment of disease. Aiming to overcome the main drawbacks of the oral route and to maintain patient compliance high, the engineering of innovative drug delivery systems administrable by mucosal routes has come to light and gained the interest of the scientific community due to the possibility to dramatically change pharmacokinetics. In addition, to achieve the goal of mucosal drug administration, the development of biomaterials has been refined to fit specific applications. The present review initially describes the potential of nano-drug delivery systems conceived for mucosal administration by diverse non-parenteral routes (e.g., oral, inhalatory, etc.). Then, the benefit of the incorporation of mucoadhesive polymers into the structure of these innovative pharmaceutical products to prolong their residence time in the administration site and the release of the drug cargo will be discussed with focus in the developments of the last decade. In addition, the regulatory status of the most extensively used mucoadhesive polymers will be emphasized. Finally, a thorough overview of the different pharmaceutical applications of mucoadhesive polymers will be addressed.
Keywords
PEIHECABCPLGAHPMCCMCPCLMSTHPCPVPPMSAPIPAAPLARGDGRASDOPAGITMPIIBDALGHSV-2MPTDDSBRBi.v.BCSFBLMWHMLVTMCSLNspHEMANaCMCPBCAPMAA3-aminophenyl boronic acidAPBAα-l-guluronic acidβ-d-mannuronic acidNano-DDSUS FDANPsArginine-Glycine-Aspartic AcidAlginateEDTAEthylenediaminetetraacetic acidUS Food and Drug AdministrationAIDSgenerally recognized as safeTuberculosisInflammatory bowel diseaseTrimethyl chitosanPharmaceutical research and developmentNMRCNSGastrointestinal tractBBBBlood–brain barrieracquired immunodeficiency syndromeDrug delivery systemcentral nervous systemNuclear magnetic resonance spectroscopyPharmacokineticsblood–retinal barrierBlood–cerebrospinal fluid barrierCerebrospinal fluidCSFMethylcelluloseActive Pharmaceutical IngredientNanoparticlesSolid lipid nanoparticlesLow molecular weight heparinhydroxyethyl celluloseHydroxypropyl celluloseHydroxypropyl methylcelluloseHIVhuman immunodeficiency virusherpes simplex virus type 2PAMAMMultilamellar vesiclepoly(lactic-co-glycolic acid)Poly(epsilon-caprolactone)Poly(lactic acid)Poly(methacrylic acid)Poly(methyl methacrylate)PMMApoly(hydroxyethyl methacrylate)Poly(vinyl pyrrolidone)poly(amidoamine)Poly(ethylene imine)poly(ethylene oxide)Poly(ethylene glycol)poly(acrylic acid)PEGPEOCarboxymethyl cellulosecarboxymethyl cellulose sodium salti.n.ChitosanGalactomannanGlucomannan
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Alejandro Sosnik, José das Neves, Bruno Sarmento,